FoRx Therapeutics: Valuation, Funding & Investors
FoRx Therapeutics is a privately held clinical-stage biotechnology company developing precision therapeutics that target the DNA Damage Response (DDR) in treatment-resistant cancers. The company’s lead product candidate, FORX-428, is an oral small-molecule PARG inhibitor in Phase 1 development for advanced solid tumors, aimed at treating cancers resistant to PARP inhibitors.
Leadership & Board
- Current Number of Employees
- 34
- Current LinkedIn Followers
- 7,575
Latest Estimated Valuation
- Total Amount Raised
- $50M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $50M
- Latest Funding Round
- Series A
Employee Trend
FoRx Therapeutics had 34 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
FoRx Therapeutics had 7,575 followers as of November 16, 2026. The number of followers increased by 28 (0.37%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 18, 2025 | Series A | $50.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| M Ventures | Series A |
| EQT Life Sciences | Series A |
| Novartis Venture Fund | Series A |
| Pfizer Ventures | Series A |
Similar Companies
A snapshot of private companies similar to FoRx Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis







